Loading
MPL is the receptor that tells the bone marrow to make platelets. Romiplostim and eltrombopag switch it on to raise platelet counts; in some myeloproliferative neoplasms a mutant partner protein, calreticulin, grips it and keeps it on. This dossier gathers the 2 products (0 approved), 4 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
MPL has no kinase of its own and signals through JAK2, so JAK inhibitors act below it whatever the driver. The INCA033989 record explains that CALR frameshift mutations give the protein a positively charged tail that lets it bind and activate MPL on the cell surface, switching on JAK-STAT signalling without thrombopoietin.
| Modality | Withdrawn or failed |
|---|---|
| Small molecule 2 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 3 | Active | PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer | - | ||
| 2 | Completed | Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia in Low or Intermediate I Myelodysplastic Syndrome (MDS) | - | ||
| 2 | Completed | A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects With Acute Myelogenous Leukaemia (AML) Receiving Induction Chemotherapy | - | ||
| 2 | Active | A Phase II Randomized Placebo-controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"MPL" OR ABSTRACT:"MPL" OR TITLE:"thrombopoietin receptor" OR ABSTRACT:"thrombopoietin receptor" OR TITLE:"TPO receptor" OR ABSTRACT:"TPO receptor" OR TITLE:"TPOR" OR ABSTRACT:"TPOR" OR TITLE:"THPOR" OR ABSTRACT:"THPOR" OR TITLE:"CD110" OR ABSTRACT:"CD110") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MPL (thrombopoietin receptor), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/mpl.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/mpl.json. Licence CC BY-NC 4.0.